Melissa Fischer, MD
Urogynecology and Reconstructive Pelvic Surgery · Royal Oak, MINPI 1326067067
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Medtronic at 35.2% of the total.
Across 216 payments — averaging $49.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Boston Scientific$3K
- Ferring Pharmaceuticals Inc.$563
- Astellas Pharma US Inc$512
- AbbVie$294
- Caldera Medical, Inc$259
- plus $3K from 33 others
Across 25 payments — averaging $5406.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$135K
What the payments were for
- Consulting fees$7107%
- Speaking & faculty fees$2,10020%
- Travel & lodging$1,42413%
- Food & beverage$6,39060%
- Education$1151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 36 | $3,775 |
| Boston Scientific | 9 | $2,779 |
| Ferring Pharmaceuticals Inc. | 8 | $563 |
| Astellas Pharma US Inc | 30 | $512 |
| AbbVie(2 entities) | 19 | $294 |
| Caldera Medical, Inc | 2 | $259 |
| Dendreon Pharmaceuticals LLC | 10 | $256 |
| Axonics, Inc. | 6 | $191 |
| Biotissue Holdings Inc. | 1 | $174 |
| Sumitomo Pharma America, Inc. | 14 | $150 |
| Johnson & Johnson | 8 | $146 |
| Merck | 5 | $134 |
| Urogen Pharma, Inc. | 4 | $133 |
| Olympus America Inc. | 3 | $125 |
| Myriad Genetic Laboratories, Inc. | 1 | $122 |
| Antares Pharma, Inc. | 6 | $118 |
| AstraZeneca | 7 | $116 |
| Tolmar Pharmaceuticals, Inc. | 6 | $101 |
| Coloplast | 5 | $97 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $58 |
| 180 Medical, Inc. | 3 | $56 |
| Urovant Sciences Inc | 4 | $55 |
| Sun Pharmaceutical Industries Inc. | 3 | $54 |
| Blue Earth Diagnostics | 3 | $54 |
| Progenics Pharmaceuticals, Inc. | 2 | $46 |
| Teleflex LLC | 2 | $44 |
| Bayer | 2 | $44 |
| Tolmar, Inc. | 2 | $31 |
| Rochester Medical Corporation | 2 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Novartis | 1 | $27 |
| Ambu Inc. | 1 | $25 |
| Immunitybio, Inc. | 1 | $24 |
| Tempus AI, Inc | 1 | $24 |
| Therapeuticsmd, Inc. | 2 | $23 |
| Clarus Therapeutics Inc. | 1 | $22 |
| Calyxo, Inc. | 1 | $20 |
| Halozyme Inc | 1 | $16 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL FEMALE SUI$2,270
- INTERSTIM$1,107
- NURO$710
- FIRMAGON$487
- UPSYLON$266
- Desara$259
- INTERSTIM ICON$153
- Prolaris$122
How this compares
$10,739 in reported general payments places this provider in the 80th percentile of 33 urogynecology and reconstructive pelvic surgery providers in Michigan.
See all urogynecology and reconstructive pelvic surgery providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 582 | $563,195 |
| Mirabegron ErMirabegron | 207 | $118,249 |
| Methenamine Hippurate | 459 | $35,965 |
| Solifenacin Succinate | 490 | $21,995 |
| Fosfomycin Tromethamine | 77 | $21,017 |
| Tolterodine Tartrate ErTolterodine Tartrate | 184 | $18,863 |
| Trospium Chloride | 251 | $17,854 |
| Trospium Chloride ErTrospium Chloride | 44 | $9,019 |
| PremarinEstrogens, Conjugated | 16 | $8,936 |
| Estradiol | 116 | $6,974 |
| Oxybutynin Chloride ErOxybutynin Chloride | 121 | $4,344 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 437 | $4,191 |
| Tamsulosin Hcl | 183 | $3,357 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 25 | $2,991 |
| Finasteride | 127 | $2,159 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $512 | $563,195582 claims |
| PfizerPremarin | $13 | $8,93616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 33 urogynecology and reconstructive pelvic surgery providers in Michigan.
Other urogynecology and reconstructive pelvic surgery in Royal Oak
- Gabrielle RohrerRoyal Oak$5K
- Pradeep NagarajuRoyal Oak$5K
- Jaber SaadRoyal Oak$2K
- Jannah ThompsonNorton Shores$474K
- Jason BennettGrand Rapids$68K
- Priyanka GuptaAnn Arbor$39K
- Jason CruffDearborn$12K
- John DelanceyAnn Arbor$11K
- Anne CameronBrighton$7K
- Ali LuckWest Bloomfield$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.